AR095594A1 - Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos - Google Patents

Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos

Info

Publication number
AR095594A1
AR095594A1 ARP140101219A ARP140101219A AR095594A1 AR 095594 A1 AR095594 A1 AR 095594A1 AR P140101219 A ARP140101219 A AR P140101219A AR P140101219 A ARP140101219 A AR P140101219A AR 095594 A1 AR095594 A1 AR 095594A1
Authority
AR
Argentina
Prior art keywords
overweight
antibiotics
methods
patients
obesos
Prior art date
Application number
ARP140101219A
Other languages
English (en)
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of AR095594A1 publication Critical patent/AR095594A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere de manera general a métodos para tratar infecciones en pacientes con sobrepeso u obesos usando antibióticos. Reivindicación 40: El método de la reivindicación 39, donde el compuesto es delafloxacina. Reivindicación 41: El método de cualquiera de las reivindicaciones anteriores, donde la dosificación está comprendida entre aproximadamente 10 mg/día y aproximadamente 600 mg/día.
ARP140101219A 2013-03-15 2014-03-17 Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos AR095594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790179P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095594A1 true AR095594A1 (es) 2015-10-28

Family

ID=51581190

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101219A AR095594A1 (es) 2013-03-15 2014-03-17 Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos

Country Status (14)

Country Link
US (3) US20160058750A1 (es)
EP (1) EP2969004A4 (es)
JP (2) JP6617097B2 (es)
KR (1) KR102237887B1 (es)
AR (1) AR095594A1 (es)
AU (2) AU2014239965A1 (es)
BR (1) BR112015023044A8 (es)
CA (1) CA2904387C (es)
CL (1) CL2015002759A1 (es)
HK (1) HK1219690A1 (es)
IL (1) IL241113A0 (es)
MX (1) MX2015011760A (es)
TW (1) TWI641372B (es)
WO (1) WO2014152332A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
US20160243190A1 (en) 2015-02-23 2016-08-25 Theravance Biopharma Antibiotics Ip, Llc Doses and methods for administering telavancin
CN107216353B (zh) * 2016-03-21 2020-05-19 山东诚创医药技术开发有限公司 一种头孢洛林酯咪唑盐的精制方法
SG11201811345TA (en) 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056872A2 (en) * 2008-11-15 2010-05-20 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions

Also Published As

Publication number Publication date
EP2969004A4 (en) 2016-09-21
US20160058750A1 (en) 2016-03-03
HK1219690A1 (zh) 2017-04-13
BR112015023044A8 (pt) 2021-09-28
KR102237887B1 (ko) 2021-04-07
US20240165100A1 (en) 2024-05-23
TWI641372B (zh) 2018-11-21
CA2904387C (en) 2021-12-07
AU2019200483A1 (en) 2019-02-14
AU2014239965A1 (en) 2015-09-24
JP2019196401A (ja) 2019-11-14
KR20150133762A (ko) 2015-11-30
JP2016513689A (ja) 2016-05-16
EP2969004A1 (en) 2016-01-20
CA2904387A1 (en) 2014-09-25
MX2015011760A (es) 2016-06-10
BR112015023044A2 (pt) 2017-07-18
TW201513862A (zh) 2015-04-16
CL2015002759A1 (es) 2016-04-22
JP6617097B2 (ja) 2019-12-04
WO2014152332A1 (en) 2014-09-25
US20220257584A1 (en) 2022-08-18
IL241113A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
AR089993A1 (es) Macrociclos peptidomimeticos
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
ECSP13012844A (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
AR101740A1 (es) Terapia de combinación y composiciones
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
UY33993A (es) Análogo macrocíclico de la sangliferina y su método de producción
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure